To include your compound in the COVID-19 Resource Center, submit it here.

Analyst Picks & Changes

Analyst Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 8/19 cls
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) Piper Jaffray Edward Tenthoff Upgrade Overweight (from neutral) -4% $6.62
Tenthoff also raised his target to $12 from $10 ahead of anticipated Phase I data next quarter for ALN-TTR01 to treat transthyretin (TTR)-mediated amyloidosis and ALS-PCS to treat hypercholesterolemia. ALN-TTR01 is a stable nucleic acid lipid particle (SNALP)-formulated RNAi targeting the

Read the full 823 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE